All In Biotech

Drug Trial Radar · NCT00610051

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

Phase 3 Study of Alprostadil Continuous Intravenous Infusion to Maintain Clinical Stability in Severe Heart Failure Patients

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Nov 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Biopeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Feb 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after randomization in participants with advanced HF with reduced ejection fraction(HFrEF).

Conditions

  • End Stage Cardiac Failure
  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • NYHF Class III-IV

Interventions

  • AlprostadilDrug

    central venous access continuous delivery with 500mcg/48 hours in active arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to all-cause mortality (defined as death, heart transplant, LVAD placement, mechanical circulatory support, or HF event(* hospitalization for HF or unplanned intravenous therapy for HF, ie diurectics, inotropes, vassopressors, or vasodilators.)Time frame: 6 months infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical university Vienna

    Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.